The Public Policy Implications of the Abbott Split
This article was originally published in RPM Report
Executive Summary
Abbott’s decision to spin-off proprietary pharmaceuticals as a stand-alone company is all about Wall Street: investors cheered the move for “unlocking value” by removing the giant shadow cast by Humira over the diversified base business. But it is also an important touchstone for all the key public policy themes playing out in the biopharma space after health care reform.